BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30712002)

  • 21. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.
    Malcikova J; Pavlova S; Kozubik KS; Pospisilova S
    Hum Mutat; 2014 Jun; 35(6):663-71. PubMed ID: 24415659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
    Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
    Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection and Functional Analysis of TP53 Mutations in CLL.
    Pavlova S; Smardova J; Tom N; Trbusek M
    Methods Mol Biol; 2019; 1881():63-81. PubMed ID: 30350198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
    Dufour A; Palermo G; Zellmeier E; Mellert G; Duchateau-Nguyen G; Schneider S; Benthaus T; Kakadia PM; Spiekermann K; Hiddemann W; Braess J; Truong S; Patten N; Wu L; Lohmann S; Dornan D; GuhaThakurta D; Yeh RF; Salogub G; Solal-Celigny P; Dmoszynska A; Robak T; Montillo M; Catalano J; Geisler CH; Weisser M; Bohlander SK
    Blood; 2013 May; 121(18):3650-7. PubMed ID: 23525797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.
    Zenz T; Kröber A; Scherer K; Häbe S; Bühler A; Benner A; Denzel T; Winkler D; Edelmann J; Schwänen C; Döhner H; Stilgenbauer S
    Blood; 2008 Oct; 112(8):3322-9. PubMed ID: 18689542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PRIMA-1
    Jaskova Z; Pavlova S; Malcikova J; Brychtova Y; Trbusek M
    Leuk Res; 2020 Feb; 89():106288. PubMed ID: 31924585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
    Chin-Yee B; Sadikovic B; Chin-Yee IH
    Br J Haematol; 2020 Mar; 188(5):652-660. PubMed ID: 30836431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia.
    Pinto AM; Papa FT; Frullanti E; Meloni I; Tita R; Caselli R; Fallerini C; Lopergolo D; Cetta F; Mencarelli MA; Bocchia M; Gozzetti A; Renieri A
    Br J Haematol; 2019 Feb; 184(4):657-659. PubMed ID: 29460960
    [No Abstract]   [Full Text] [Related]  

  • 31. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.
    Pospisilova S; Gonzalez D; Malcikova J; Trbusek M; Rossi D; Kater AP; Cymbalista F; Eichhorst B; Hallek M; Döhner H; Hillmen P; van Oers M; Gribben J; Ghia P; Montserrat E; Stilgenbauer S; Zenz T;
    Leukemia; 2012 Jul; 26(7):1458-61. PubMed ID: 22297721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.
    Wang C; Wang X
    Int J Clin Exp Pathol; 2013; 6(7):1223-9. PubMed ID: 23826404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
    Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
    Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
    Shindiapina P; Brown JR; Danilov AV
    Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency Of TP53 Gene Mutation In Patients With Chronic Lymphocytic Leukaemia.
    Qadir H; Nasir N; Qadir N; Adil SN; Tanzeem H; Qadir A
    J Ayub Med Coll Abbottabad; 2020; 32(4):523-526. PubMed ID: 33225656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.
    Pekova S; Mazal O; Cmejla R; Hardekopf DW; Plachy R; Zejskova L; Haugvicova R; Jancuskova T; Karas M; Koza V; Smolej L; Bezdickova L; Kozak T
    Leuk Res; 2011 Jul; 35(7):889-98. PubMed ID: 21232794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.
    Griffin R; Wiedmeier-Nutor JE; Parikh SA; McCabe CE; O'Brien DR; Boddicker NJ; Kleinstern G; Rabe KG; Bruins L; Brown S; Bonolo de Campos C; Ding W; Leis JF; Hampel PJ; Call TG; Van Dyke DL; Kay NE; Cerhan JR; Yan H; Slager SL; Braggio E
    Blood Adv; 2023 Jul; 7(13):3169-3179. PubMed ID: 36877634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation.
    Yu L; Kim HT; Kasar S; Benien P; Du W; Hoang K; Aw A; Tesar B; Improgo R; Fernandes S; Radhakrishnan S; Klitgaard J; Lee C; Getz G; Setlur SR; Brown JR
    Clin Cancer Res; 2017 Feb; 23(3):735-745. PubMed ID: 27503198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation.
    Rudenko HC; Else M; Dearden C; Brito-Babapulle V; Jones C; Dexter T; Fenwick K; Mackay A; Ashworth A; Matutes E; Gonzalez D; Catovsky D; Morgan GJ
    Leuk Lymphoma; 2008 Oct; 49(10):1879-86. PubMed ID: 18949611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of locus specific sub-clone separation by fluorescence in situ hybridization in suspension in chronic lymphocytic leukemia.
    Do CH; Bailey S; Macardle C; Thurgood LA; Lower KM; Kuss BJ
    Cytometry A; 2017 Nov; 91(11):1088-1095. PubMed ID: 29024486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.